Business Progress - The company announced on February 11, 2026, that its subsidiary Tianxin Pharmaceutical and its branch Baiyunshan Pharmaceutical Factory have 24 products, including Cefuroxime Sodium for Injection, proposed for selection in the national drug procurement program. The total sales revenue for these products is projected to be 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% of revenue [1]. Subsidiary Development - On February 2 and 3, 2026, subsidiaries Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. received changes to their drug production licenses from the Guangdong Provincial Drug Administration, involving new production addresses or adjustments to production workshops aimed at improving production efficiency. However, this is expected to have no significant impact on current financials [2]. Product R&D Progress - On February 6, 2026, the company's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol Soft Capsules, which are used to treat calcium metabolism disorders [3]. Funding Movements - According to data disclosed on February 5, 2026, JPMorgan Chase increased its holdings in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, 2026, raising its ownership stake to 9.12%. Additionally, the company emphasized in its Q3 2025 report that it would continue to promote its dividend policy and capital operations, but the timing of related events should be confirmed with the latest announcements [4].

Core Viewpoint - Li Zhaoting, the former richest man in Shijiazhuang, has been detained by the police, which has significant implications for his companies, particularly Dongxu Group and its subsidiaries [2][3][19]. Group 1: Company Overview - Dongxu Group Limited, the largest shareholder of Jinying Fund with a 66% stake, is controlled by Li Zhaoting [17]. - At his peak, Li Zhaoting controlled three listed companies: Dongxu Optoelectronics, Dongxu Blue Sky, and Jialinjie [20]. Group 2: Financial Misconduct - From 2015 to 2019, under Li Zhaoting's leadership, Dongxu Group engaged in extensive financial fraud, inflating revenues by 47.825 billion yuan and profits by 13.001 billion yuan [21]. - The highest single-year inflation of cash funds reached 44.79 billion yuan, and the group fraudulently issued corporate bonds worth 3.5 billion yuan in 2018 [21]. Group 3: Current Status and Future Implications - Following a series of upheavals, only Jialinjie remains as a listed company under the "Dongxu system" [23]. - Li Zhaoting's control over Jinying Fund is in jeopardy due to a lifetime ban from the securities market imposed by the China Securities Regulatory Commission in June 2025 [25]. - The shares of Jinying Fund held by Dongxu Group have been frozen multiple times by the court due to significant debt disputes [25].

Core Viewpoint - Guangzhou Pharmaceutical Group Co., Ltd. has disclosed significant anti-corruption results in a recent annual report, highlighting the company's commitment to integrity and governance [1] Group 1: Anti-Corruption Measures - The report details 17 cases of corruption over the past year, with a total amount involved of approximately 170 million yuan [1] - Internal sources indicate that these cases have been communicated internally as warnings to staff [1] Group 2: Disciplinary Actions - In 2025, the disciplinary inspection and supervision agencies of Guangzhou Pharmaceutical Group and its subsidiaries investigated 30 individuals and imposed 42 party disciplinary and administrative penalties [1] - The 17 typical cases involved key personnel from major subsidiaries, including Zhongyi Pharmaceutical, Wanglaoji Pharmaceutical, Baiyunshan Pharmaceutical Factory, He Jigong Pharmaceutical Factory, and Huanhong Traditional Chinese Medicine [1]

重要提醒！！！为防失联，请"星标"我们！进入无冕财经公众号，点击右上角"..."，再" "，以便您及时接收每篇推送~ wumiancaijing.com 最热的泛财经新闻，都在这儿了。 2月12日，广药集团纪律检查委员会发布文件，集中通报去年17起严重违纪违法典型案例，其中包括此前备受关注的广药集团腐败"窝案"。 文件通报的17起要案中，涉及广药集团旗下中一药业、王老吉药业、白云山制药总厂、何济公制药厂等多家核心子公司，涉案人职位上到董事长、总经 理、副总经理、部门总监、经理等各级管理人员，下至保卫科科长。腐败行为集中在药品原材料及包装材料采购、药品代理经销、广告投放与业务承揽、 款项结算、职务晋升等关键领域，部分人员还存在依托他人职权谋取私利、销售假药等严重违法行为，涉案总金额超2亿元。 ▲图片来自网络。 资讯整理：小冕 编辑：陈涧 设计：岚昇 广药集团腐败窝案15人被判刑 涉案超2亿，李楚源处理结果未出 本文由无冕财经（wumiancaijing）整理发布 从已披露的结果看，已有15人因受贿罪或销售假药罪被判处有期徒刑。其中，王老吉药业是被点名频次最高的企业，违法违纪行为涉及广药集团和王老吉 药业广告与媒 ...

Company Developments - Baiyunshan announced that its subsidiary Tianxin Pharmaceutical and Baiyunshan Pharmaceutical Factory plan to participate in the national drug procurement for 24 products, with projected sales revenue of 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% [2] - Baiyunshan's subsidiaries, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received production license changes from the Guangdong Provincial Drug Administration to enhance production capacity and efficiency, although no significant financial impact is expected in the current period [3] Product Development - Baiyunshan's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [4] Financial Movements - Morgan Stanley increased its stake in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, raising its ownership to 9.12% [5] - The company reported a year-on-year increase in revenue and net profit in its Q3 2025 report, emphasizing its ongoing dividend policy and capital operations [5]

上述通报显示，在此次通报的17人中，15人因受贿罪或销售假药罪被判处有期徒刑，刑期最高的为十二 年有期徒刑（方广宏），有2人涉嫌相关违法已受党纪政务处分，尚未提及判决结果。 责任编辑：何俊熹 2月12日消息，据报道，曾在2024年引发社会各界高度关注的广药集团反腐风波在近日终于有了结论。 中共广州医药集团有限公司（简称广药集团）纪律检查委员会近日公布了《穗药集纪2025》16号文件， 通报了广药集团2025年度一系列典型违纪违法案例，其中就包括2024年底引发社会各界高度关注的广药 集团腐败"窝案"，涉案人员包括广药集团原党委委员、副总经理张春波；广州王老吉药业股份有限公司 原总裁、董事长方广宏；广州王老吉药业股份有限公司营销中心常务副总经理赵敏等17人。 2月12日消息，据报道，曾在2024年引发社会各界高度关注的广药集团反腐风波在近日终于有了结论。 中共广州医药集团有限公司（简称广药集团）纪律检查委员会近日公布了《穗药集纪2025》16号文件， 通报了广药集团2025年度一系列典型违纪违法案例，其中就包括2024年底引发社会各界高度关注的广药 集团腐败"窝案"，涉案人员包括广药集团原党委委员、副总经理张春 ...

中证500价值ETF华夏（159617）业绩比较基准为中证智选500价值稳健策略指数收益率，管理人为华夏 基金管理有限公司，基金经理为荣膺，成立（2022-06-09）以来回报为49.01%，近一个月回报为 6.00%。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 2月12日，中证500价值ETF华夏（159617）开盘跌0.67%，报1.477元。中证500价值ETF华夏（159617） 重仓股方面，太阳纸业开盘涨0.83%，鄂尔多斯跌1.11%，桐昆股份跌0.38%，九州通跌0.19%，浙江龙 盛跌0.55%，雅戈尔涨0.00%，梅花生物涨0.18%，韵达股份涨0.00%，长沙银行涨0.10%，白云山涨 0.00%。 来源：新浪基金∞工作室 ...

Group 1 - The core viewpoint of the article highlights the company's strategy to enhance the value of the Wanglaoji brand by expanding its distribution network and collaborating with major restaurant platforms [1] - The company is focusing on promoting bottled beverages and exploring new product lines, including original flavor herbal tea and various fruit-flavored juice products, to cultivate a second growth curve [1] - In the functional beverage segment, the company has launched Wanglaoji Flash Recharge Electrolyte Water, indicating its commitment to innovation in product offerings [1]

Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable penicillin sodium, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is approved in a dosage of 0.96g (1.6 million units) [1] - This medication is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1]